» Articles » PMID: 34034542

An 8-gene DNA Methylation Signature Predicts the Recurrence Risk of Cervical Cancer

Overview
Journal J Int Med Res
Publisher Sage Publications
Specialty General Medicine
Date 2021 May 26
PMID 34034542
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study examined the predictive utility of DNA methylation for cervical cancer recurrence.

Methods: DNA methylation and RNA expression data for patients with cervical cancer were downloaded from The Cancer Genome Atlas. Differentially methylated genes (DMGs) and differentially expressed genes were screened and extracted correlation analysis. A support vector machine (SVM)-based recurrence prediction model was established using the selected DMGs. Cox regression analysis and receiver operating characteristic curve analysis were used for self-evaluation. The Gene Expression Omnibus (GEO) database was applied for external validation. Functional enrichment was determined using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses.

Results: An eight-gene DNA methylation signature identified patients with a high risk of recurrence (area under the curve = 0.833). The SVM score was an independent risk factor for recurrence (hazard ratio [HR] = 0.418; 95% confidence interval [CI] = 0.26-0.67). The independent GEO database analysis further supported the result.

Conclusion: An eight-gene DNA methylation signature predictive of cervical cancer recurrence was identified in this study, and this signature may help identify patients at high risk of recurrence and improve clinical treatment.

Citing Articles

MRI radiomics and nutritional-inflammatory biomarkers: a powerful combination for predicting progression-free survival in cervical cancer patients undergoing concurrent chemoradiotherapy.

Yan Q, Wu M, Zhang J, Yang J, Lv G, Qu B Cancer Imaging. 2024; 24(1):144.

PMID: 39449107 PMC: 11515587. DOI: 10.1186/s40644-024-00789-2.


Promising predictive molecular biomarkers for cervical cancer (Review).

Lizano M, Carrillo-Garcia A, De La Cruz-Hernandez E, Castro-Munoz L, Contreras-Paredes A Int J Mol Med. 2024; 53(6).

PMID: 38606495 PMC: 11090266. DOI: 10.3892/ijmm.2024.5374.


A robust panel based on genomic methylation sites for recurrence-free survival in early hepatocellular carcinoma.

Long G, Zhao L, Tang B, Zhou L, Mi X, Su W Heliyon. 2023; 9(9):e19434.

PMID: 37809660 PMC: 10558510. DOI: 10.1016/j.heliyon.2023.e19434.

References
1.
Takahashi M, Tsukamoto Y, Kai T, Tokunaga A, Nakada C, Hijiya N . Downregulation of WDR20 due to loss of 14q is involved in the malignant transformation of clear cell renal cell carcinoma. Cancer Sci. 2016; 107(4):417-23. PMC: 4832870. DOI: 10.1111/cas.12892. View

2.
Li X, Cai Y . Methylation-Based Classification of Cervical Squamous Cell Carcinoma into Two New Subclasses Differing in Immune-Related Gene Expression. Int J Mol Sci. 2018; 19(11). PMC: 6275080. DOI: 10.3390/ijms19113607. View

3.
Bao X, Anastasov N, Wang Y, Rosemann M . A novel epigenetic signature for overall survival prediction in patients with breast cancer. J Transl Med. 2019; 17(1):380. PMC: 6889649. DOI: 10.1186/s12967-019-2126-6. View

4.
Moarii M, Boeva V, Vert J, Reyal F . Changes in correlation between promoter methylation and gene expression in cancer. BMC Genomics. 2015; 16:873. PMC: 4625954. DOI: 10.1186/s12864-015-1994-2. View

5.
Jones P, Laird P . Cancer epigenetics comes of age. Nat Genet. 1999; 21(2):163-7. DOI: 10.1038/5947. View